Ishita Drugs and Industries Limited has issued a regulatory disclosure to BSE Limited regarding an upcoming Board of Directors meeting. The meeting is scheduled to be held on Tuesday, 03rd November, 2026.
The primary agenda for the board meeting includes:
- Consideration, approval, and taking on record the Unaudited Financial Results of the Company for the quarter ended 30th September, 2026
- Any other matter with permission of the Chair
The disclosure also notes that in accordance with the Company's Code of Conduct for Prevention of Insider Trading framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the Company's securities by Designated Persons remains closed. The trading window closure period is from Thursday, 01st October, 2026 until 48 hours after the announcement of the Unaudited Financial Results for the quarter ended 30th September, 2026.
The filing is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and is addressed to The Department of Corporate Services, The BSE Limited at Floor No. 25, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001.
The document is signed by Jagdishprasad Gokulchand Agrawal (DIN: 01031687), Managing Director of the Company.
Company identification details: CIN No. L24231GJ1992PLC017054, D & B D-U-N-S Number - 65-018-0359